9
Participants
Start Date
May 31, 2013
Primary Completion Date
August 31, 2017
Study Completion Date
September 30, 2017
Brentuximab Vedotin
Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Collaborators (1)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
Millennium Pharmaceuticals, Inc.
INDUSTRY
Fondazione Michelangelo
OTHER